Sens. Chuck Grassley and Ron Wyden threatened Cigna Corp.’s Express Scripts business with a subpoena after the lawmakers said the pharmacy benefit manager failed to comply with an investigation of rising insulin costs. Meanwhile, lawmakers seek answers on any influence unofficial advisers had on President Donald Trump's decision to endorse a risky antidepressant for veterans.
from Kaiser Health News https://ift.tt/2uyMU68
February 27, 2020
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Campaigning Ramps Up as South Dakota Voters Decide on Medicaid ExpansionCUSTER, S.D. — A silver minivan decorated with a large sticker reading “Love Your Neighbor Tour” recently circumnavigated South Dakota. Catholic nuns, Protestant pastors, a synagogue president, and a Muslim nonprofit professi… Read More
Will Covid Spike Again This Fall? 6 Tips to Help You Stay SafeLast year, the emergence of the highly transmissible omicron variant of the covid-19 virus caught many people by surprise and led to a surge in cases that overwhelmed hospitals and drove up fatalities. Now we’re learning that… Read More
Comienzan a estar disponibles audífonos de venta libre desde $199Desde el lunes 17 de octubre, miles de consumidores podrán comprar audífonos directamente en las tiendas, y a precios dramáticamente más bajos, gracias a una ley federal de 2017 que está entrando en vigencia. Durante décadas,… Read More
Lawsuit by KHN Prompts Government to Release Medicare Advantage AuditsFederal health officials have agreed to make public 90 audits of private Medicare Advantage health plans for seniors that are expected to reveal hundreds of millions of dollars in overcharges to the government. The Centers fo… Read More
After Congress Fails to Add Dental Coverage, Medicare Weighs Limited Benefit ExpansionProposed changes in Medicare rules could soon pave the way for a significant expansion in Medicare-covered dental services, while falling short of the comprehensive benefits that many Democratic lawmakers have advocated. That… Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment